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Population studiesThe aim is to examine the temporal trends of hip fracture incidence in Portugal by sex and age groups, and
explore the relation with anti-osteoporotic medication.
From the National Hospital Discharge Database, we selected from 1st January 2000 to 31st December 2008, 77,083
hospital admissions (77.4%women) caused by osteoporotic hip fractures (low energy, patients over 49 years-age),
with diagnosis codes 820.x of ICD 9-CM. The 2001 Portuguese population was used as standard to calculate direct
age-standardized incidence rates (ASIR) (100,000 inhabitants). Generalized additive and linear models were used
to evaluate and quantify temporal trends of age speciﬁc rates (AR), by sex.
We identiﬁed 2003 as a turning point in the trend of ASIR of hip fractures in women. After 2003, the ASIR
in women decreased on average by 10.3 cases/100,000 inhabitants, 95% CI (−15.7 to −4.8), per 100,000
anti-osteoporotic medication packages sold. For women aged 65–69 and 75–79 we identiﬁed the same turning
point. However, for women aged over 80, the year 2004 marked a change in the trend, from an increase to a
decrease. Among the population aged 70–74 a linear decrease of incidence rate (95% CI) was observed in both
sexes, higher for women:−28.0% (−36.2 to−19.5) change vs−18.8%, (−32.6 to−2.3).
The abrupt turning point in the trend of ASIR of hip fractures in women is compatible with an intervention,
such as a medication. The trends were different according to gender and age group, but compatible with the
pattern of bisphosphonates sales.
© 2013 Elsevier Inc. All rights reserved.Introduction
Identifying and understanding trends of hip fracture incidence is
important, not only as a way for planning future medical resources
and treating patients but also in planning effective preventivemeasures
[1]. Costs related to hip fractures are not only restricted to hospitaliza-
tion but also to the long recovery time and assistance that these patients
require [2,3]. Public health interventions can be taken using knowledge
gathered from epidemiologic studies using secondary data. These
studies can provide valuable information with the use of reliable
data on a national basis [4,5].4150-180 Porto, INEB, Instituto
7.
t.economou@exeter.ac.uk
neves@gmail.com (N. Neves),
ineb.up.pt (M.F. Pina).
rights reserved.The bone quality impairment is associated to aging and elevates the
risk of osteoporotic fractures, particularly in post-menopausal women.
Furthermore, an excessive pathologic decrease in bone strength can be
prevented either by the use of medicaments or by changing activity and
nutritional behaviour [6]. Osteoporotic hip fractures are more common
among women over the age of 49 years and grows exponentially with
aging. With the increase of life expectancy the range of population at
risk is considerable, enhancing the need to analyze trends by age groups.
In 2008, life expectancy at age 65 in the European Union (27 member
states) was 17.2 and 20.7 years for males and females respectively [7].
In Portugal, the same indicator with data from 2009 to 2011 was 16.9
and 20.2 respectively (last available data) [7,8]. Moreover, the elderly
form the fastest growing age group inmostwestern countries thus aggra-
vating the burden of osteoporosis.
In Portugal there are no national studies addressing the trend of hip
fractures. However, internationally several studies have been conducted
reporting trends of age-standardized incidence rates of hip fractures [1].
Nevertheless the results are not consensual: increasing, decreasing and
431S.M. Alves et al. / Bone 53 (2013) 430–436stable trends have been reported, which may reﬂect different stages in
the epidemic curve. The results regarding the shape of the trends as
well an existing pattern in men have also differ. Studies in Finland [9]
and Australia [10,11] have reported rates of hip fractures compatible
with a non-linear trend. However in Finland the decrease pattern was
observed in both genders, whereas in Australia only women presented
a decreasing pattern. Rates presenting linear decreases have been
reported by studies in Belgium [12], Denmark [13], Canada [14], United
States [15] for both genders and Spain just for women [16]. Unique
causes are impossible to assess, nevertheless studies have pointed out
different plausible reasons, according to their results, namely medica-
tion for osteoporosis [10,11,16] or other interventions [13,14].
It is important to explore time trends of age-standardized incidence
rates of hip fractures although they may hide different underlying
trends by age groups thus leading to incorrect conclusions. And since
hip fractures affect awide range of ages, these studiesmay help uncover
unequal patterns and meaningful associations with the preventive pro-
cedures undertaken by different countries.
The aim of this work is to examine the temporal trends of hip fracture
incidence in Portugal by sex and age group, and explore its relation with
anti-osteoporotic medication.
Materials and methods
Study area
The study area was Continental Portugal with a population of
10,135,309 inhabitants in 2008. In 2000 therewere 3,298,922 inhabitants
aged 50 years or over, increasing by 11.9% in 2008 (n=3,691,104) [8],
in contrast with a decrease of −0.6% in the population aged under 50
in the same period.
Data
Population data was the annual ofﬁcial estimates, per sex and
5-year age groups, except for 2001, which was a census year.
We used data from the National Hospital Discharge Register
(NHDR). The use of this administrative database is mandatory since
1997 in all Portuguese public hospitals, and compiles information on
all discharges such as gender, age, admission and discharge date; ﬁrst
cause of admission (and up to 19 secondary causes) coded according
to the International Classiﬁcation of Diseases, version 9, Clinical Modiﬁ-
cation (ICD9-CM); main diagnosis (and up to 19 secondary diagnoses),
also coded according to the ICD9-CM; clinical interventions (up to 20);
surgical interventions; hospital providing the care; outcome (deceased,
discharge to home, discharge to another hospital); length of stay (LOS)
and patient's place of residence.
In Portugal, access to the national health-care system is free and
universal and due to the high costs involved, hip fractures are primarily
treated in public hospitals. Therefore hip fractures are highly docu-
mented and the NHDR records the total number of admissions with a
diagnosis of hip fracture nationwide.
The quality of the NHDR is accessed regularly by both internal
(hospitals) and external (ACSS— Central Administration of theNational
System) auditors [17].Table 1
Summary of statistics of in-patients characteristics in portugal (2000–2008).
Variable 2000 2001 2002 2003
Men
No. of admissions 1752 1947 1780 1989
Age (mean; (SD)) 77.6 (10.02) 77.4 (10.03) 78.0 (9.92) 77.6 (9.94)
Women
No. of admissions 6086 6537 6295 6814
Age (mean; (SD)) 80.3 (8.59) 80.5 (8.64) 80.9 (8.61) 80.7 (8.72)We selected all discharges from 1st January 2000 to 31st December
2008 of individuals aged 50 years or over, with a diagnosis of hip fracture
(codes ICD9-CM 820.x) caused by a low or moderate trauma. We ex-
cluded cases of bone cancer, readmissions for orthopedic after-care
or complications in surgical and medical care (codes ICD9-CM:
170.x, 171.x, V54.x, 996.4), the exclusion expression was applied to
all 20 ﬁelds containing diagnosis, and represented 0.8% of the cases.
To account for misclassiﬁcation on the diagnosis ﬁeld other actions
were taken, namely revisions were excluded based on procedures
codes (81.53 Revision of hip replacement, not otherwise speciﬁed)
representing a total of 0.08% of the cases. In addition we also excluded
cases with length of stay inferior to 5 days, that did not went to a surgery
and that were transferred to another hospital, because the ﬁrst hospital-
ization could be just to stabilize the patient, these represent 1.1% of the
cases.
In Portugal it is not possible to have database linkage between
NHDR and prescriptions so the data on medication was only available
for the entire population, and therefore it was not possible to access
sales desegregated by sex and age groups, or have the number of patients
treated. Data was provided by the National Authority of Medicines and
Health Products (INFARMED). We analyzed, on a national level, the
number of anti-osteoporotic medication packages sold from 2000 to
2008 through prescriptions made in the National Health System
(NHS). We used the total number of anti-osteoporotic medication for
the entire population to explain the trend of hip fractures in women,
based on our preliminary results that showedno increasing or decreasing
trends in ASIR for men. The stable incidence rates of hip fractures among
men is compatiblewith the lowprescription of anti-osteoporoticmedica-
tion for men identiﬁed in other countries [12] and information contained
in Portuguese national guidelines [18,19] which focus the prevention of
osteoporosis in women. The medications analyzed were those indicated
as agents that can act on the inhibition of bone loss or promote directly
bone formation [20,21] with a high evidence level of reducing the risk
of a hip fracture: bisphosphonates, calcitonin, hormonal replacement
therapy (HRT), Strontium ranelate and Selective Estrogen Receptor
Modulators (Reloxifene) aswell as vitamin D (recommended to be pre-
scribed in association with the medications mentioned [19]).
We used the Portuguese population from the 2001 census, avail-
able from the Statistics Portugal (Instituto Nacional de Estatística —
INE) as the standard for calculating the direct age-standardized inci-
dence rates (ASIR) per 100,000 inhabitants by gender.
We calculated age-speciﬁc rates (AR) by gender, using population
counts in the census year of 2001 and ofﬁcial estimates for all the
other years. Five-year age groups were used from 50 to 84 years of
age and a wider group comprising all patients older than 84.
In addition, we calculated the 95% Conﬁdence Intervals (95% CI) for
each rate according to the methods described in Morris and Gardner
(2000) [22].
Statistical analysis
WeusedGeneralized AdditiveModels (GAMs) to investigate changes
in the trends of incidence rates. These models are ﬂexible as they incor-
porate a non-parametric component that is implemented using spline
functions (smoothers) and can reveal possible non-linearities in the2004 2005 2006 2007 2008
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432 S.M. Alves et al. / Bone 53 (2013) 430–436effect of the predictors [23]; for this studywewere interested in the pos-
sible non-linear effect of time in the incidence rates. The GAMs were
used in an exploratory manner [24] to identify visually the relationship
of time to themean incidence rate. For the caseswhere the smooth func-
tion of time was statistically signiﬁcant, we ﬁtted Generalized Linear
Models (GLMs) to quantify formally changes in trends. For somemodels,
the smooth non-parametric function was linear so we ﬁtted a GLMwith
a linear relationship in time. In cases where the smooth function
exhibited a turning point, we used piecewise regression with the identi-
ﬁed turning points as the cut points, similar to what is described in chap-
ter 12 of Faraway, 2006 [24].
We modeled the ASIR as a Gaussian random variable using year as
an independent predictor. The GLM results consisted of a linear regres-
sion coefﬁcient (the parameter of variable year), in this case the average
increase/decrease (depending on the signal of the coefﬁcient) in the
rates by an increment of one year. For women, in order to evaluate
how sales of anti-osteoporoticmedication affect the ASIR,we ﬁtted sim-
ilar models using the number of packages sold as the independent
variable.
We also conducted the analysis on the AR by gender using a GAM
followed by a GLM to quantify statistically signiﬁcant trends. In both
cases we assumed that the incidence rates for each age and sex
group have a different Poisson distribution, therefore for each group
we explored a separate model. Whenever necessary, a negative bino-
mial distribution was used to account for overdispersion [24]. For the
AR trend analysis, the natural logarithm of the number of cases was
modeled as function of year (nonparametric for GAM) and an offset
factor of log (population size of each year). The results of the GLM
were expressed as Incidence Rate Ratios (IRR), a relative risk measure
representing the factor by which the rate increases/decreases with an
increase of a year: a value lower than one represents a decrease in
risk between one year and the next (decrease trend), a value higher
than one represents an increased risk (increased trend), whereas an
IRR equal to one represents an equal risk between two consecutive
years (a steady trend). The relative estimated percentage change for
each of the periods identiﬁed as having a statistically signiﬁcant trend
was calculated by dividing the difference between estimated rates in
the ﬁnal and initial year in the period by the estimated rate in the initial
year of the period ([estimated rate ﬁnal year-estimated rate initial
year]/estimated rate initial year). For all measures we calculated the
95% CI.
For the purposes of modeling the age and sex groups separately, the
older age groups were aggregated so that the oldest group included
patients over 79 years of age. This was done in order to avoid
underdispersion.
Statistical analysis was performed using statistical software R version
2.14.1 (Project for Statistical Computing), the mgcv and MASS packages
for trend analysis.
A simplistic version of the models implemented is:
(1) GAM models for ASIR rate~s(year) and rate~s(number of anti-
osteoporotic medication packages sold)
(2) GLM model for ASIR rate~year and rate~number of anti-
osteoporotic medication packages sold
(3) GAM models for AR log(cases)~s(year)+log (population)
(4) GLM models for AR log(cases)~year+log (population)Ta
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)Results
During the study period we identiﬁed 77,083 hip fractures, 77.4% in
women (mean age (standard deviation (SD)) at admission 81.1 (SD 8.5)
years old versus 78.3 (SD 10.1) and (p-valueb0.0001) for women and
men respectively. Table 1 shows number of admissions and mean age
at admission, according to the year of admission whereas Table 2
shows the ASIR and age-speciﬁc rates during the period of study.
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Fig. 1. Smooth function of time in AR for women aged: 55–59 years-old (panel A), 65–69 years-old (panel B), 75–79 years-old (panel C) and over 79 years-old (panel D).
433S.M. Alves et al. / Bone 53 (2013) 430–436The age groups where the smooth function of time was statistically
signiﬁcant, indicating a statistically signiﬁcant trend of incidence rates
according to time, were 55–59, 65–69, 70–74, 75–79 and over
79 years-old and over in women and 70–74 years-old in men. The fol-
lowing Figs. 1 and 2 show the statistically signiﬁcant smooth functions
of time by age groups in both sexes and in Table 3we present the results
for the age-speciﬁc rates using the quantiﬁcation given by the GLM
models.
We identiﬁed a linear effect of time in the age groups 55–59 for
women and 70–74 for both genders (Figs. 1 and 2). For the other age2000 2002 2004 2006 2008
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Fig. 2. Smooth function of time in AR for women aged 70–74groups in women, we identiﬁed a point within the period which deter-
mines a turn in the trend; these turning points are either increasing to
decreasing or an alteration in the velocity of decrease. For women aged
65–69 and 75–79 years, 2003 can be visually identiﬁed from Fig. 1 as
the year where a change occurred. For older women aged more than
79, we identiﬁed 2004 as the turning point in the trend.
In Fig. 3 it can be observed the evolution of anti-osteoporotic medi-
cation sales during the period of study. It can clearly be observed that
after 2003 the number of biphosphonates packages is themajor respon-
sible for the total amount of anti-osteoporotic packages sold.year
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years-old (panel A) and for men aged 70–74 (panel B).
Table 3
Incidence rate ratios (IRR), percentage relative change and corresponding 95% CI calculated with GLM.
Age-gender group IRR (95% CI) % Change (95% CI)
Men Period Period
70–74 2000–2008 2000–2008
0.974 (0.952 to 0.997) −18.81 (−32.56 to −2.25)
Women Period Period
55–59 2000–2008 2000–2008
0.961 (0.932 to 0.991) −27.36 (−43.18 to −7.18)
65–69 2000–2003 2003–2008 2000–2003 2003–2008
1.027 (0.986 to 1.070) 0.937 (0.914 to 0.961) 8.28 (−4.23 to 22.52) −27.63 (−36.21 to −17.94)
70–74 2000–2008 2000–2008
0.959 (0.945 to 0.973) −28.36 (−36.24 to −19.52)
75–79 2000–2003 2003–2008 2000–2003 2003–2008
1.00 (0.980 to 1.020) 0.968 (0.957 to 0.981) −0.48 (−5.78 to 7.17) −14.79 (−19.89 to −9.38)
>79 2000–2004 2004–2008 2000–2004 2004–2008
1.013 (1.005 to 1.023) 0.972 (0.963 to 0.980) 5.71 (1.98 to 9.58) −10.86 (−13.87 to −7.76)
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of time only amongwomen (Fig. 4, panel A). This effect is non-linear and
the year 2003 was identiﬁed as the turning point in the trend.
The linear model for the ASIR in women for the period 2000–2003
revealed that for each year, the incidence rate increased on average
by 5.1 cases per 100,000 inhabitants with a 95% CI (−1.6 to 11.7).
As for the period 2003–2008, the decrease trend was statistically sig-
niﬁcant with an average decrease of 9.6 cases per 100,000 inhabitants
with a 95% CI (−13.4 to −5.7).
The non-linear effect of total number of anti-osteoporotic packages
sold in ASIR (Fig. 4 panel B) is identical to that of time in ASIR (Fig. 4
panel A) with the same turning point identiﬁed in 2003. From 2003
the decrease of 10.2 cases per 100,000 inhabitants with 100,000 pack-
ages sold was statistically signiﬁcant: 95% CI (−15.7 to−4.8).
Discussion
In this population-based retrospective study, the year 2003
appeared as a turning point in the time trend of age-standardized in-
cidence rate (ASIR) of hip fracture in women. The observed trend
from 2000 to 2008 with a clear and abrupt decrease change in
2003, is compatible with an intervention on national level. WhenFig. 3. Sales of medication for the prevention of osteoanalysing by sex, the anti-osteoporotic medication packages sold,
in each of the years within the study period, had the same impact
on the trend of ASIR for women, with the same turning point relating
to 2003 sales.
After 2003, with the decrease of HRT, the total number of anti-
osteoporotic packages are manly bisphosphonates, suggesting that
the massive increase in prescription of these medications was the
intervention responsible for the change in the trends of ASIR. The rap-
idly increase of bisphosphonates sales can be the result of Bone and
Joint Decade actions, that raised awareness to prevention, translating
in a higher amount of individuals protected and consequently a de-
crease of incidence rates. However, in Portugal the number of patients
treated cannot be assessed, as it is not possible to linkage different
health related databases. Furthermore, the results by gender and
age group are compatible with this hypothesis. The turning points
were only present in women and the change was ﬁrst observed in
the age groups which are the target of these prescriptions in Portugal.
Regardless of no causal relationship being able to be attributed is an
ecological study, it acknowledges an important aspect that needs
further clariﬁcation.
The existence of a turning point can be identiﬁed visually in other
studies [9–11] where the change was attributed to bisphosphonatesporosis and reduction of fracture risk in Portugal.
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Fig. 4. Smooth function of time in age-standardized incidence rates (ASIR) for women (panel A) and of number of packages of anti-osteoporotic medication sold in age-standardized
incidence rates (ASIR) for women (panel B).
435S.M. Alves et al. / Bone 53 (2013) 430–436[10,11]. However, when the trend is linear and present in bothmen and
women [13–15] questions the extent of bisphosphonates inﬂuence
were raised [13,14]. Results similar to ours were observed in a study
from Australia [11] and a following study from the same population
[10] showed that a decrease in bisphosphonates sales was followed by
an increase of hip fracture incidence, underlying the possibility of the
trends of hip fracture incidence rates being driven by bisphosphonates.
A change in the trend could be attributed to other factors, however it
is unlikely that a change in the demographic and socioeconomic charac-
teristics of the population could occur so promptly that impacted on hip
fracture incidence so abruptly has our results pointed out. Other inter-
ventions, such as falls prevention campaigns, are usually focused on
the elderly age groups (over 80 years old) and were not implemented
nationwide in Portugal. Falls prevention actions in Portugal are sparse,
conducted locally in some health centers (local impact) and they did
not occur simultaneously, therefore it is not likely that such local actions
would explain the accentuated turning points in the time trends of ASIR
nationwide.
Our study has limitations that in our perspective do not invalidate
the results. The relation between the number of bisphosphonates sold
and age-standardized incidence rates for women can be questioned
because no confounders were used to adjust the effect. In our opinion,
the traditional risk factors for osteoporotic hip fractures that could be
seen as confounders, such as socioeconomic status or cohort effect,
would not have a sudden impact on ASIR, since they do not vary
abruptly in time. In our study, the period of 9 years would not be
long enough to observe major differences in traditional risk factors
at ecological level and even so, they would not have an abrupt impact
capable of a turning point in the time trends at national level, we
would expect a continuous linear trend like the one obtained on
70–74 age group for both genders.
The strength of our study can be attributed to the data and the statis-
tical methods applied. Our data covers a wide geographic scope, with
data containing both hip fractures and medication sales on a national
level (excluding the 5% of the population that lives in the autonomous
regions), which overmatch local studies. In this paper we analyzed
data from several perspectives using ﬂexible models, which to our
knowledge have not been used on epidemiological studies of hip frac-
tures. These methods allowed the identiﬁcation of non-linear effects,
complemented with parametric models that allowed the quantiﬁcation
of the decreasing patterns, after the abrupt change. The trends of osteo-
porotic hip fractures require analysis not only of the age-standardized
incidence rates by gender (which can hide unequal patterns by age
groups) but also disaggregate analysis by age groups, since the risk in-
creases exponentially with age and the population at risk may require
differentiated care.
The incidence rates of hip fractures showed a decreasing trendwith a
well deﬁned turning point in some age groups. Nevertheless the number
of fractures is still raising and with the aging of the population this prob-
lem tends to be aggravated, increasing the costs of treatment and rehabil-
itation of patients. We identiﬁed trends of hip fractures at national leveland these results may help making better decisions, it is important to
have similar studies, in Portugal and other countries, in the following
years to help understanding the role of anti-osteoporotic medication on
hip fracture incidence, especially with the introduction of strontium
ranelate that proved to have a positive impact on some parameters of
hip structure, namely bone mineral density [25], but with inconclusive
results regarding the decrease of hip fracture risk [26].
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